Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Enoxaparin a cost-effective choice for acute PE

    This is a preview of subscription content, log in to check access.

    Rights and permissions

    Reprints and Permissions

    About this article

    Cite this article

    Enoxaparin a cost-effective choice for acute PE. Pharmacoecon. Outcomes News 488, 7 (2005). https://doi.org/10.2165/00151234-200504880-00019

    Download citation

    Keywords

    • Pulmonary Embolism
    • Enoxaparin
    • Unfractionated Heparin
    • Inpatient Treatment
    • Acute Pulmonary Embolism